Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase

21 Oct 2022

Abstract excerpt

In AML SF3B1 mutations are recurrently found, most frequently in AML-MRC [ 1 ] and were shown to be highly specific for secondary AML (s-AML) arising post MDS or MDS/MPN [ 2 ]. Thus, the presence of SF3B1 mutations is considered as diagnostic criteria for AML-MR according to the 5th edition of the WHO classification (WHO 2022; [ 3 ]). Here, we address the prognostic impact of SF3B1 mutations in AML and evaluate...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Retinoids in leukemia and cellular processes
Share to Vascular Tumors and Angiosarcomas

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36271152
DOI: 10.1038/s41375-022-01734-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phasePMID 36271152Read ↗

SF3B1 mutated MDS: Blast count, genetic co-abnormalities and their impact on classification and prognosis.Semantic proximity Read ↗

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogeneticsSemantic proximity Read ↗

Pathologic Spectrum and Molecular Landscape of Myeloid Disorders Harboring SF3B1 Mutations.Semantic proximity Read ↗

Clinical Characteristics and Molecular Profiling of SF3B1-Mutated Myelodysplastic Syndrome (MDS) in a Real-World Practice.Semantic proximity Read ↗

Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes.Semantic proximity Read ↗

Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.Semantic proximity Read ↗

Prognostic impact of clonal representation of myelodysplasia-related gene mutations in acute myeloid leukemiaSemantic proximity Read ↗

Prognostic impact of myelodysplasia-related gene mutations in ELN-2022 favorable-risk acute myeloid leukemia subtypes.Semantic proximity Read ↗

MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similarities.Semantic proximity Read ↗

Many faces of SF3B1-mutated myeloid neoplasms: concurrent mutational profiles contribute to the diverse clinical and morphologic features.Semantic proximity Read ↗

RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.Semantic proximity Read ↗

Chronic myelomonocytic leukemia with ring sideroblasts/SF3B1 mutation presents with low monocyte count and resembles myelodysplastic syndromes with-RS/SF3B1 mutation in terms of phenotype and prognosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.